AU2007207341B2 - Method of treatment, prophylaxis and diagnosis of pathologies of the bone - Google Patents

Method of treatment, prophylaxis and diagnosis of pathologies of the bone Download PDF

Info

Publication number
AU2007207341B2
AU2007207341B2 AU2007207341A AU2007207341A AU2007207341B2 AU 2007207341 B2 AU2007207341 B2 AU 2007207341B2 AU 2007207341 A AU2007207341 A AU 2007207341A AU 2007207341 A AU2007207341 A AU 2007207341A AU 2007207341 B2 AU2007207341 B2 AU 2007207341B2
Authority
AU
Australia
Prior art keywords
bone
gpc3
subject
expression
gene
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2007207341A
Other languages
English (en)
Other versions
AU2007207341A1 (en
Inventor
Peter John Anderson
Anna Kathleen Coussens
Barry Crampton Powell
Angela Mary Van Daal
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Women's & Children's Health Research Institute Inc
Original Assignee
Womens & Childrens Health Res Institute Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2006900307A external-priority patent/AU2006900307A0/en
Application filed by Womens & Childrens Health Res Institute Inc filed Critical Womens & Childrens Health Res Institute Inc
Priority to AU2007207341A priority Critical patent/AU2007207341B2/en
Publication of AU2007207341A1 publication Critical patent/AU2007207341A1/en
Assigned to WOMEN'S & CHILDREN'S HEALTH RESEARCH INSTITUTE INCORPORATED reassignment WOMEN'S & CHILDREN'S HEALTH RESEARCH INSTITUTE INCORPORATED Alteration of Name(s) of Applicant(s) under S113 Assignors: CHILD HEALTH RESEARCH INSTITUTE INC
Application granted granted Critical
Publication of AU2007207341B2 publication Critical patent/AU2007207341B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pathology (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
AU2007207341A 2006-01-20 2007-01-19 Method of treatment, prophylaxis and diagnosis of pathologies of the bone Ceased AU2007207341B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2007207341A AU2007207341B2 (en) 2006-01-20 2007-01-19 Method of treatment, prophylaxis and diagnosis of pathologies of the bone

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
AU2006900307 2006-01-20
AU2006900307A AU2006900307A0 (en) 2006-01-20 Method of treatment and diagnosis
PCT/AU2007/000055 WO2007082352A1 (en) 2006-01-20 2007-01-19 Method of treatment, prophylaxis and diagnosis of pathologies of the bone
AU2007207341A AU2007207341B2 (en) 2006-01-20 2007-01-19 Method of treatment, prophylaxis and diagnosis of pathologies of the bone

Publications (2)

Publication Number Publication Date
AU2007207341A1 AU2007207341A1 (en) 2007-07-26
AU2007207341B2 true AU2007207341B2 (en) 2012-05-10

Family

ID=38287201

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2007207341A Ceased AU2007207341B2 (en) 2006-01-20 2007-01-19 Method of treatment, prophylaxis and diagnosis of pathologies of the bone

Country Status (8)

Country Link
US (1) US20100330085A1 (enExample)
EP (1) EP1991274A4 (enExample)
JP (1) JP2009523739A (enExample)
CN (1) CN101426536A (enExample)
AU (1) AU2007207341B2 (enExample)
CA (1) CA2637350A1 (enExample)
NZ (1) NZ569697A (enExample)
WO (1) WO2007082352A1 (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0707349D0 (en) * 2007-04-17 2007-05-23 Renovo Ltd Medicaments and methods for accelerating wound healing
EP2167976A2 (en) * 2007-05-29 2010-03-31 President And Fellows Of Harvard College Molecules involved in regulation of osteoblast activity and osteoclast activity, and methods of use thereof
JP5694776B2 (ja) * 2007-12-11 2015-04-01 エピゲノミクス アーゲー 細胞増殖性障害の解析のための方法及び核酸
EP2245459A1 (en) 2008-01-23 2010-11-03 Herlev Hospital Ykl-40 as a general marker for non-specific disease
US8580520B2 (en) 2008-09-15 2013-11-12 Herlev Hospital YKL-40 as a marker for gastrointestinal cancers
GB0922085D0 (en) * 2009-12-17 2010-02-03 Cambridge Entpr Ltd Cancer diagnosis and treatment
WO2011088163A1 (en) 2010-01-14 2011-07-21 President And Fellows Of Harvard College Methods for modulating skeletal remodeling and patterning by modulating shn2 activity, shn3 activity, or shn2 and shn3 activity in combination
EP2556379B1 (en) * 2010-10-28 2014-07-09 Avicenna Research Institute A 38 kda form of prelp as new diagnosis and therapeutic target
US20140155420A1 (en) * 2011-01-10 2014-06-05 The Regents Of The University Of Colorado, A Body Corporate Inhibitors of eya2
CN103517717B (zh) * 2011-02-16 2017-10-17 康奈尔大学 增强细胞介导的免疫的方法
AU2012253204A1 (en) * 2011-05-06 2013-04-18 Women's And Children's Health Research Institute Inc Method of treatment and prophylaxis of pathologies of the bone
CN109295218B (zh) * 2018-12-11 2020-05-19 南京医科大学 环状RNA标志物hsa_circ_0001788及其应用
CN114015767B (zh) * 2021-11-18 2023-06-02 南京市儿童医院 一种鉴别颅缝早闭的血清circRNA标志物及其应用
CN114657121B (zh) * 2022-03-23 2023-07-25 新乡医学院 LOX1基因作为流体剪切力作用下BMSCs成骨分化促进剂的应用
CN114774546B (zh) * 2022-04-27 2023-04-18 江苏省人民医院（南京医科大学第一附属医院） 一种与人骨肉瘤相关的分子标记物trim22及其应用
CN116217721A (zh) * 2023-02-16 2023-06-06 复旦大学附属中山医院 一种C14orf78免疫组织化学抗体及其制备方法与应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004058949A2 (en) * 2002-12-24 2004-07-15 Amgen Inc. Wnt-1 inhibitory factor-1 (wif-1) molecules and uses thereof
WO2004092410A2 (en) * 2003-04-15 2004-10-28 Thiesen Hans-Juergen Method for diagnosing rheumatoid arthritis or osteoarthritis
US20050171012A1 (en) * 2001-09-10 2005-08-04 Takeda Chemical Industries, Ltd. Preventives/remedies for bone/joint diseases

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4018653A (en) 1971-10-29 1977-04-19 U.S. Packaging Corporation Instrument for the detection of Neisseria gonorrhoeae without culture
US4018884A (en) 1975-06-26 1977-04-19 Hoffmann-La Roche Inc. Fluorogenic materials and labeling techniques
US4016043A (en) 1975-09-04 1977-04-05 Akzona Incorporated Enzymatic immunological method for the determination of antigens and antibodies
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US4331647A (en) 1980-03-03 1982-05-25 Goldenberg Milton David Tumor localization and therapy with labeled antibody fragments specific to tumor-associated markers
US4469863A (en) 1980-11-12 1984-09-04 Ts O Paul O P Nonionic nucleic acid alkyl and aryl phosphonates and processes for manufacture and use thereof
US4424279A (en) 1982-08-12 1984-01-03 Quidel Rapid plunger immunoassay method and apparatus
US4501728A (en) 1983-01-06 1985-02-26 Technology Unlimited, Inc. Masking of liposomes from RES recognition
US4897255A (en) 1985-01-14 1990-01-30 Neorx Corporation Metal radionuclide labeled proteins for diagnosis and therapy
US5235033A (en) 1985-03-15 1993-08-10 Anti-Gene Development Group Alpha-morpholino ribonucleoside derivatives and polymers thereof
US5034506A (en) 1985-03-15 1991-07-23 Anti-Gene Development Group Uncharged morpholino-based polymers having achiral intersubunit linkages
US4744981A (en) 1985-10-17 1988-05-17 Neorx Corporation Trichothecene antibody conjugates
US4837028A (en) 1986-12-24 1989-06-06 Liposome Technology, Inc. Liposomes with enhanced circulation time
EP0329184A3 (en) 1988-02-19 1990-05-23 Neorx Corporation Antimers and antimeric conjugation
US4988496A (en) 1988-05-31 1991-01-29 Neorx Corporation Metal radionuclide chelating compounds for improved chelation kinetics
US5216141A (en) 1988-06-06 1993-06-01 Benner Steven A Oligonucleotide analogs containing sulfur linkages
US5143854A (en) 1989-06-07 1992-09-01 Affymax Technologies N.V. Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof
US5744101A (en) 1989-06-07 1998-04-28 Affymax Technologies N.V. Photolabile nucleoside protecting groups
US5800992A (en) 1989-06-07 1998-09-01 Fodor; Stephen P.A. Method of detecting nucleic acids
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
EP0438803B1 (en) 1990-01-26 1997-03-12 Immunomedics, Inc. Vaccines against cancer and infectious diseases
US5279833A (en) 1990-04-04 1994-01-18 Yale University Liposomal transfection of nucleic acids into animal cells
US5386023A (en) 1990-07-27 1995-01-31 Isis Pharmaceuticals Backbone modified oligonucleotide analogs and preparation thereof through reductive coupling
US5602240A (en) 1990-07-27 1997-02-11 Ciba Geigy Ag. Backbone modified oligonucleotide analogs
GB9022788D0 (en) 1990-10-19 1990-12-05 Cortecs Ltd Pharmaceutical formulations
DE69132531T2 (de) 1990-12-06 2001-09-13 Affymetrix, Inc. (N.D.Ges.D.Staates Delaware) Verbindungen und ihre Verwendung in einer binären Synthesestrategie
US5283185A (en) 1991-08-28 1994-02-01 University Of Tennessee Research Corporation Method for delivering nucleic acids into cells
US5644048A (en) 1992-01-10 1997-07-01 Isis Pharmaceuticals, Inc. Process for preparing phosphorothioate oligonucleotides
US5854217A (en) 1992-09-28 1998-12-29 Bearsden Bio, Inc. Allosteric modulators of the NMDA receptor and their use in the treatment of CNS disorders and enhancement of CNS function
US5637684A (en) 1994-02-23 1997-06-10 Isis Pharmaceuticals, Inc. Phosphoramidate and phosphorothioamidate oligomeric compounds
US5807522A (en) 1994-06-17 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods for fabricating microarrays of biological samples
US5908635A (en) 1994-08-05 1999-06-01 The United States Of America As Represented By The Department Of Health And Human Services Method for the liposomal delivery of nucleic acids
US5830645A (en) 1994-12-09 1998-11-03 The Regents Of The University Of California Comparative fluorescence hybridization to nucleic acid arrays
US6096716A (en) 1994-12-12 2000-08-01 The Board Of Regents, The University Of Texas System Liposome-mediated transfection of central nervous system cells
WO2005078124A2 (de) * 2004-02-16 2005-08-25 Proteosys Ag Diagnostische marker für krebs
US7485657B2 (en) * 2004-05-12 2009-02-03 Boehringer Ingelheim Pharmaceuticals, Inc. Anti-cytokine heterocyclic compounds
DE602005024502D1 (de) * 2004-07-09 2010-12-16 Chugai Pharmaceutical Co Ltd Anti-glypican-3-antikörper

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050171012A1 (en) * 2001-09-10 2005-08-04 Takeda Chemical Industries, Ltd. Preventives/remedies for bone/joint diseases
WO2004058949A2 (en) * 2002-12-24 2004-07-15 Amgen Inc. Wnt-1 inhibitory factor-1 (wif-1) molecules and uses thereof
WO2004092410A2 (en) * 2003-04-15 2004-10-28 Thiesen Hans-Juergen Method for diagnosing rheumatoid arthritis or osteoarthritis

Also Published As

Publication number Publication date
JP2009523739A (ja) 2009-06-25
EP1991274A4 (en) 2009-06-10
AU2007207341A1 (en) 2007-07-26
NZ569697A (en) 2012-01-12
CN101426536A (zh) 2009-05-06
US20100330085A1 (en) 2010-12-30
CA2637350A1 (en) 2007-07-26
EP1991274A1 (en) 2008-11-19
WO2007082352A1 (en) 2007-07-26

Similar Documents

Publication Publication Date Title
AU2007207341B2 (en) Method of treatment, prophylaxis and diagnosis of pathologies of the bone
Galaviz-Hernandez et al. Plac8 and Plac9, novel placental-enriched genes identified through microarray analysis
AU2008286361B2 (en) IVIG modulation of chemokines for treatment of multiple sclerosis, Alzheimer's disease, and Parkinson's disease
EP2420575B1 (en) Marker for prognosis of liver cancer
AU2006210794A1 (en) Biomarkers for tissue status
US20160115540A1 (en) Prodrugs and drugs
BRPI0616090A2 (pt) métodos e materiais para identificação da origem de um carcinoma de origem primária desconhecida
JP2009525041A (ja) 癌またはその素因の早期検出のための方法およびキット
US20120052079A1 (en) Compositions, Kits, and Methods for Predicting Anti-Cancer Response to Anthracyclines
Shan et al. Methylation of bone SOST impairs SP7, RUNX2, and ERα transactivation in patients with postmenopausal osteoporosis
Bahn et al. Genomic structure and in vivo expression of the human organic anion transporter 1 (hOAT1) gene
Jiang et al. SOX7 suppresses endothelial-to-mesenchymal transitions by enhancing VE-cadherin expression during outflow tract development
US20130011411A1 (en) Methods and compositions for the diagnosis, prognosis, and treatment of cancer
EP2561089A2 (en) Method of determining the metastatic potential of a tumor
Velasco-Velázquez et al. Reduced paxillin expression contributes to the antimetastatic effect of 4-hydroxycoumarin on B16-F10 melanoma cells
JP6551967B2 (ja) 肝細胞がんの転移性再発リスクの予測方法
Cheval et al. Plasticity of mouse renal collecting duct in response to potassium depletion
KR100568724B1 (ko) 담관암 유전자 마커 및 이를 이용한 담관암 진단킷트
CN109593771B (zh) 一种人类map2k5第1100位碱基突变基因及其检测试剂盒
WO2007044622A1 (en) Use of mif and mif pathway agonists
CN107022635B (zh) Acadl基因及其表达产物在制备腹主动脉瘤诊治产品中的应用
CN113648425B (zh) Plk1抑制剂和csnk1d/e抑制剂对肿瘤细胞具有协同抑制作用
KR101845590B1 (ko) 유전자를 이용한 폐암 예후예측용 조성물
CN111197088B (zh) Adamtsl3作为腹主动脉瘤诊治标志物的应用
US20060147930A1 (en) Amplified and overexpressed gene in colorectal cancers

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired